Relaxin Receptor 4 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $47.00 $105.00 $322.00 | 45 | |
L-NAME is a nitric oxide synthase inhibitor that can inhibit Relaxin Receptor 4 by reducing nitric oxide levels, which is a known mediator of relaxin signaling, thereby attenuating the signal transduction normally facilitated by Relaxin Receptor 4 activation. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD 173074, a fibroblast growth factor receptor inhibitor, can inhibit Relaxin Receptor 4 by blocking the signaling pathways downstream of FGFR, which may intersect with relaxin signaling pathways, thereby diminishing the functional response of Relaxin Receptor 4. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB 431542 is an inhibitor of the TGF-β receptor, which can inhibit Relaxin Receptor 4 by preventing TGF-β signaling that could be involved in the same physiological responses as relaxin, such as extracellular matrix remodeling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can inhibit Relaxin Receptor 4 by halting the PI3K/Akt pathway, which is crucial for cell survival and proliferation and may intersect with relaxin-mediated physiological processes, thereby inhibiting Relaxin Receptor 4's function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632, a ROCK inhibitor, can inhibit Relaxin Receptor 4 by altering the actin cytoskeleton dynamics and cell motility, which are cellular processes potentially influenced by relaxin signaling through its receptor. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin, an inhibitor of BMP signaling, can inhibit Relaxin Receptor 4 by blocking BMP pathways that might share downstream signaling components with relaxin, affecting similar biological outcomes such as reproductive system function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an MEK inhibitor that can inhibit Relaxin Receptor 4 by blocking the MEK/ERK pathway, which is integral to cellular proliferation and differentiation, processes that may be regulated by relaxin signaling via its receptor. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
GW9662, a PPARγ antagonist, can inhibit Relaxin Receptor 4 by preventing PPARγ-dependent transcriptional activation, which could intersect with relaxin-regulated gene expression and subsequent physiological responses mediated by Relaxin Receptor 4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, can inhibit Relaxin Receptor 4 by suppressing the mTOR pathway, which impacts cellular growth and metabolism, processes that could be influenced by relaxin signaling through Relaxin Receptor 4. | ||||||
JNJ-38877605 | 943540-75-8 | sc-364516 sc-364516A | 2 mg 10 mg | $126.00 $365.00 | 1 | |
JNJ-38877605, a c-Met kinase inhibitor, can inhibit Relaxin Receptor 4 by obstructing HGF/c-Met signaling, which may be involved in similar cellular responses as relaxin, such as cell migration and invasion, thus inhibiting the functional activity of the receptor. | ||||||